Real-world effectiveness of risankizumab in Crohn’s disease: a pan UK retrospective cohort study

Frontline Gastroenterology 2026 Open access

Read full text
Authors: Alexander Thomas Elford, Nathan Constantine‐Cooke, Krishna Shah, Sarah C Faloon, Magdalini Manti, Benjamin Zaré, Michael Colwill, Jie Han Yeo, Umair Akbani, Hannah Morgan, Robert J Mulligan, Chandni Radia
+38 more David L. Young, Fakhirah Badrulhisham, Sean Michael Morris, Zoheb Anwar-Hashim, James Henry Arthur Hassall, Mithun Thomas, Lovesh Dyall, Jennie Clough, Taha Mahmood, Aboalgasim Mohammed, Vikram Mohanan, Emily F Brownson, Sarah Helen Hancox, Benjamin Disney, Ajay Mark Verma, John Paul Seenan, EL Johnston, Rishi Goel, Lucy Hicks, Shaji Sebastian, Melissa Fay Hale, Philip Harvey, Rachel Cooney, Tariq Ahmad, Fraser Cummings, Alexandra Kent, Andrew King, Jimmy K Limdi, Christian P. Selinger, Sara A McCartney, Richard Pollok, Peter Miles Irving, Mark Samaan, Naila Arebi, Gareth C. Parkes, The UK experience of Risankizumab in Crohn’s disease, Charlie W. Lees, Nikolas Plevris
DOI: 10.1136/flgastro-2025-103449
Cited by: 1
References: 14

Abstract

Objective Risankizumab is an interleukin-23 p19 subunit inhibitor which received approval for Crohn’s disease (CD) by UK licensing authorities in May 2023. Our aim was to evaluate the real-world outcomes of risankizumab in the UK. Design We conducted a retrospective, multicentre, cohort study of patients with CD treated with risankizumab across 25 health boards in the UK between 1 January 2021 and 1 November 2024. Our primary outcome was treatment persistence at 6 months. Our secondary endpoints were steroid-free clinical remission (Harvey-Bradshaw index

Fields of Study & Subjects

Inflammatory Bowel Disease Rheumatoid Arthritis Research and Therapies Biosimilars and Bioanalytical Methods

Publication details

Journal / source
Frontline Gastroenterology
Publisher
BMJ
Pages
flgastro–2025
Publication date
6 January 2026
Language
EN